Alfa1 antitrypsin

Also known as: α1-antitrypsin Serpin family A member 1 Alpha1 proteinase inhibitor A1PI A1AT

Therapeutic indications

Alfa1 antitrypsin is indicated for:

Emphysema in alpha1-proteinase inhibitor deficiency

Population group: both men and women, only adults (18 - 65 years old)

Alpha-1 antitrypsin is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). Patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines